Driehaus Capital TYRA Position
Exited9-Fund ConvergenceDriehaus Capital exited their position in Tyra Biosciences, Inc. (TYRA) in Q2 2024, after holding the stock for 6 quarters.
The position was first reported in Q1 2023 and has been tracked across 6 quarterly 13F filings.
TYRA is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for TYRA-300 in 230 days (Nov 30, 2026), making the timing of Driehaus's position particularly relevant.
Short interest stands at 18.6% of float with 5.5 days to cover, indicating significant bearish positioning against the stock.
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Full company profile →Short Interest
18.6%
5.5 days to cover
Driehaus Capital TYRA Position History
Frequently Asked Questions
Does Driehaus Capital own TYRA?
No. Driehaus Capital exited their position in Tyra Biosciences, Inc. (TYRA) in Q2 2024. They previously held the stock for 6 quarters.
How many hedge funds own TYRA?
9 specialist biotech hedge funds currently hold TYRA, including RA Capital Management, Boxer Capital, BVF Partners and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy TYRA?
Driehaus Capital's position in TYRA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's TYRA position increasing or decreasing?
Driehaus Capital completely exited their TYRA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TYRACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →